IsoTherapeutics Group is a radiopharmaceutical company that provides research and development services, including animal studies and early stage manufacturing for
the purpose of aiding customers and collaborators in the development of radionuclide-based drug and device products. Current collaborators include Molecular Imaging, PerkinElmer, MD Anderson
Cancer Center, University of Missouri-Columbia, Excel Diagnostics and Valco Instruments. The Company scientists, while formerly employed at The Dow Chemical Company, developed the commercial
products QUADRAMET® and Iotrex®.
Vivos, Inc. has partnered with IsoTherapeutics Group, LLC of Angleton, TX on the manufacturing and preclinical development of Y-90 based brachytherapy. The first
project between Vivos and IsoTherapeutics focuses on Vivo’s Y-90 RadioGel™ device. IsoTherapeutics is developing and executing studies, under Vivos guidance, in the manner the FDA has requested,
with the end goal of FDA clearance for the Y-90 RadioGel™ device.
“We are pleased to offer our services to Vivos and look forward to a long and outstanding collaboration that will have a significant, positive impact on the
commercialization efforts of the Vivos's Y-90 brachytherapy products,” stated R. Keith Frank, Ph.D., President and CEO of IsoTherapeutics Group.